Thank you very much for submitting your study proposing tissue specific licensing factors for ARchromatin recruitment for consideration to The EMBO Journal editorial office.
I do enclose comments from three expert referees that indicate principle interest in the paper. At the same time concerns are raised that need significant experimental revisions to substantiate the proposed, novel functions of HNF4alpha and AP-2 as tissue-specific licensing factors.
Please allow me to summarize those comments that we identified as crucial for further consideration at The EMBO Journal:
-the motif analysis needs re-assessment/re-finement to address ref#1's critique -convincing experimental evidence should be provided to confirm the proposed pioneering/recruitment function of both Hnf4alpha and AP-2 employing gene-depletion approaches (all three refs).
-please complement the ChIP-seq binding results with at least some appropriate micro-array data as requested by ref#2 -sufficient experimental detail of the highly praised, technically challenging analyses should be provided to enable reproducibility.
Conditioned on such, certainly significant amendments, I am happy to offer the possibility to submit
Major points
The current motif analysis is not convincing, and all parameters and critical procedures should be given.
(1) The ARE matrix should be obtained using a more stringent threshold to reduce false positive predictions. (2) No literature has reported finding the full-length ARE in 70%-99% of AR binding sites, suggesting that a more stringent approach is required here. (3) We scanned for the full-length ARE in Epididymis AR binding regions provided in S3, and failed to find that 99% of binding sites contain this motif as reported. (4) Following these concerns the rate of co-occurrence of over-represented cofactor motifs should be reevaluated. (e.g. Fig. 4E shows that only 25% of AR binding sites are shared by AP-2 . However, as the motif analysis identified 99% concordance between AR binding sites and the AP-2 motif, there is a strong likelihood that the current approach has generated too many false positives during motif scanning. (6) Given these issues with the motif analysis, Fig. 4D should also be regenerated, as new candidate cofactors are likely to be identified by changes to the experimental parameters.
The authors suggest that FoxA1 in prostate, Hnf4 in kidney, and AP-2 in epididymis serve as tissue-specific pioneering or licensing factors for AR. Unfortunately, while the ability to serve as a pioneer factor for AR is well-established for FoxA1, the authors did not provide any experimental evidence to support this function for Hnf4 and AP-2 . Several question arise and should be addressed: (1) Would silencing of Hnf4 and AP-2 affect AR binding in vitro? (2) According to Figures 5A -5C (top panels), would AP-2 also regulated AR binding in Prostate and Kidney under hormone replacement conditions? (3) Do these factors have cooperative effects at their common binding sites (e.g. FKBP5), or are they mutually exclusive? The authors need to perform experiments to answer these questions.
Finally, the authors collected RNA after 3 days of testosterone treatment; however, they tested AR binding after only 2 hours. Did they perform microarray analysis at different time points to match the ChIP-seq data? Early transcription events following testosterone treatment should be evaluated before drawing conclusions about differentially regulated genes in these three tissues. For example, some Cluster 5 genes appearing to be downregulated in the prostate may be first upregulated directly in Day 1 and then downregulated indirectly in Day 3.
Minor points
Details of ChIP-seq data should be included (uni-mapped reads).
Most IGV visualization can be placed in the supplemental information. Fig. 1B , AR ChIP should also be performed in Cast-Epididymis. Fig. 1C , Y scale should be consistent in each tissue. For example, "400" was used to show weak signal in Kid IgG and Cast while "300" was used to display strong signal in Cast 1 and 2. Fig. 2B , the density figure needs to be plotted using a color scale standard to the field. It is confusing to use white to show a moderate density of "4" -"6". The aggregate density curve should also be presented for each group, as weak binding seems to exist. Referee #2:
In the manuscript titled, "Tissue-specific pioneering factors guide AR binding in prostate, kidney and epididymis", Pihlajamaa and colleagues used genomic and computational approaches to examine the genome-wide profile of AR binding before and after androgen stimulation in different mouse tissues. The authors' global analyses revealed AR binding is tissue specific with a large number of AR binding sites found only in prostate, kidney, and epididymis. The authors showed the tissue specific binding of AR is due to FoxA1 in prostate, HNF4alpha in kidney, and AP-2alpha in epididymis. Moreover, they observed the binding of HNF4alpha and AP-2alpha to chromatin is similar to what has been previously shown for FoxA1 in that both factors are pre-bound to chromatin prior to androgen stimulation. This finding suggests these transcription factors are novel collaborative pioneering factors of AR. Finally, the authors showed using in situ hybridization the express of the three pioneer factors are in general tissue specific except for AP-2alpha.
Deciphering how lipophilic hormones such as androgens elicit their tissue specific effects is not only important in gaining a better understanding of their role in development but also provides useful information in designing drugs to specifically target their cognate receptors in specific tissues or organs. In this paper, the authors have generated an impressive number of genome-wide binding profiles of AR and collaborative factors in different mouse tissues to explain the tissue specific binding of AR upon androgen stimulation, however, in it's current form the work by the authors lacks any functional/wet lab evidence to support their claims that these factors (in particular for HNF4alpha and AP-2alpha) indeed function as collaborative factors of AR and are determining factors of AR genomic location in prostate, kidney and epididymis. The proofs provided by the authors are all based on association and thus require additional testing.
Major commments:
1. Assigning collaborative functions to HNF4alpha and AP-2alpha in AR binding based largely on overlapping ChIP-seq data is misleading. The authors do not show the loss of these factors have any effect (gain or loss) on AR binding, AR transcriptional activity, or androgen-dependent transcription. Previous studies (including the authors) have shown a large fraction of AR binding sites that are co-localized with FoxA1 in prostate cancer was not affected by the removal of FoxA1. This result shows that even though a factor is bound in close proximity to another it may not have any function on that factor and thus additional wet lab work needs to be performed in order to make such conclusions. The reviewer understands performing functional studies on animals may be a bit difficult, however, a quick literature search shows there are immortalized mouse cell lines representing prostate, kidney, and epididymis that may be available which the authors can test to determine whether HNF4alpha and AP-2alpha are required for AR binding and transcription.
2. The authors associated binding results (ChIP-seq) performed at 2 hr post androgen stimulation with RNA expression (microarray) analyzed 3 days after hormone stimulation. Since there is almost a 3 days difference in the binding and expression results, the conclusions the authors made regarding the direct transcriptional effects of AR on androgen regulated-genes may be due to indirect effects. Shorter times for RNA expression analysis are needed.
3. In Figure 2A , the authors showed in a Venn diagram there is a large number of unique AR binding sites in all three tissues they examined. In Figure 4A , the authors predict the unique AR binding sites in each tissue contain enriched motifs for other transcription factors. Moreover, they predict the percentage of motifs for these transcription factors in the AR binding sites to suggest these factors are likely involved in the tissue specific binding of AR. Since the authors have ChIPSeq data for the factors they predicted, is their prediction correct? For example, the authors predict in kidney-unique ARBS there are 87% HNF4alpha motifs present (prostate-unique ARBS has 48% FoxA1 motifs and epididymis-unique ARBS contains 99% AP-2alpha motifs). If the authors overlap the ChIP-seq for HNF4alpha with the kidney-unique ARBS, how much of the unique AR binding is explained by the collaborative factor? What is the overlap compared to the non-unique AR binding sites? Currently, the Venn diagram in Figure 4E shows only a general overlap of AR with each transcription factor in the different tissues. It is possible the overlap observed is due to the nonunique AR binding sites.
4. Based on current results, the title, abstract, and statements made by the authors need to be toned down.
Referee #3:
The authors report AR binding profiles in mouse tissues (prostate, kidney and epididymis). Based on on integrating this data with gene expression profiles and undertaking motif enrichment analysis they report tissue-specific AR binding profiles which are dependent on different factors depending on the tissue. AR binding in prostate is attributed to FoxA1, AR binding in kidney is attributed to HNF4 and AR binding in epididymis is attributed to AP-2 .
There are some aspects of this paper that represent a step change in the field. These are predominantly technical. It is striking that the authors have been able to generate apparently robust ChIP-seq data with good site coverage (in excess of 10,000 binding sites in a given condition) from limited tissue samples -the methods section refers to a single prostate. There needs to be an explicit comment on the quantity (mass of tissue) used in each case and the quantitative yield of chromatin from this. Given the cellular heterogeneity in the organs used the field will be highly focused on the quality of the data generated and the level of background. The authors should therefore also explicitly address the proportion of cells in each tissue which express the androgen receptor and coexpress the proposed licensing factors. Evaluating the data quality and level of background in the data is impossible currently because the accession link in the paper (GSE47194) does not work. Clinical papers, for example Ross-Innes et al., Nature 2012 led to the identification of several hundred to roughly one thousand high confidence binding sites for the ER in human breast cancers. An order of magnitude difference in number compared to this study and indeed this has led groups to work on and implement approaches such as ChIP-exo and linear amplification to enhance signal. Consequently the field will be intent on learning technical lessons from this submission.
Downstream analysis of the data needs to be more comprehensively described:-1. Attribution of sites to gene expression changes. The authors select a 100kb window. Is this an arbitrary/biased selection or is their an informatic rationale for doing so.
2. The authors have performed motif enrichment. They should comment comprehensively on the massociation between motif enrichments for particular subsets of genes/discrete biological pathways eg. E2F enrichments.
3. The presumption in the paper is that the approach has revealed tissue-specific licensing factors. Binding sites can be inert, repressive or active in their impact on transcription. A more meaningful motif enrichment would arise from a site stratification based on a better definition of the underlying chromatin landscape using histone marks.
The underlying conceptual point which is that AR recruitment is context-dependent is clear and has been proposed many times before and indeed tested in other models. This makes it an imperative to more precisely demonstrate the true tissue-specificity of these factors and the implications of the interplay between these factors for tissue-specific functions and/or organ development. As it stands this tissue-based AR 'descriptome' represents a technical leap forward based on the amounts of material used and consequently a first in these tissues but does not open up new experimental or conceptual avenues beyond that. We thank the Editors of The EMBO Journal for giving us this opportunity to submit a revised version of our manuscript (EMBO J 2013-85895) , and the Reviewers for their support and constructive comments. We believe that by addressing the issues raised during the review process we have strengthened the manuscript significantly. We hope that our manuscript is now acceptable for publication in The EMBO Journal.
Below are our point-by-point responses to the Reviewers' comments and concerns. 
Major points
Our response: The manuscript text has been modified to clarify these issues (Results p. 8, lines 10-14 and Materials and Methods p.19, lines 4-7). Parameters are now given in Materials and Methods section.
(1) The ARE matrix should be obtained using a more stringent threshold to reduce false positive predictions.
Our response: In the de novo motif search, given genomic regions are scanned for enriched motifs without any a priori information from the existing motif databases. The results from SeqPos analysis algorithm are provided as a list of putative motifs of varying length that are statistically significantly enriched (p-value and z-score) among the input sequences. The algorithm also reports the number of the input sequences that contain each particular motif. Thus, there is no ARE matrix used in the analysis parameters, and the ARE motifs depicted in Figs. 4A-C are independently produced for each of the three datasets with a p-value cut-off, and sorted on the basis of z-score.
Supplementary Table S2 provides now compilation of the results of the de novo motif analyses sorted by z-score.
(2) No literature has reported finding the full-length ARE in 70%-99% of AR binding sites, suggesting that a more stringent approach is required here.
Our response: See our responses above. The full-length ARE in 70-99% of AR binding sites are reported for the top 5000 sites, and therefore, the percentage does not reflect all sites. We have now made the text clearer in the manuscript (Legend for Fig. 4 , p. 30, lines 5-9). The stringency in the de novo motif search by SeqPos is an inherent feature of the algorithm and other than the p-value cutoff, it reports a z-score for every motif. Our conclusions are drawn on the basis of the most stringent and top enriched motifs.
(3) We scanned for the full-length ARE in Epididymis AR binding regions provided in S3, and failed to find that 99% of binding sites contain this motif as reported.
Our response: As indicated in the manuscript text and in the supplementary dataset file, Dataset S3 contains a complete list of ARBs in caput epididymis that are present in the two biological replicates (a total of 22,598 ARBs). The manuscript text and the legend for Fig. 4 state that de novo analyses were performed using ARBs unique to each tissue. Since the maximum number of input sequences in the SeqPos de novo analysis tool is 5,000, the analysis was performed by using all prostate-unique ARBs (4,915) and 5,000 kidney-unique and epididymis-unique top-enriched sites, and the percentages indicated in the Figs. 4A-C correspond to the number of hits among these 5,000 sites. This is now written more clearly in the manuscript text (p. 8, lines 10-14, Legend for Fig. 4 , p. 30, lines 5-9).
(4) Following these concerns the rate of co-occurrence of over-represented cofactor motifs should be re-evaluated. (e.g. Fig. 4C , AP-2α).
Our response: The motifs depicted in Figs. 4A-C are the only significant de novo motifs found within the ARBs unique to each tissue (besides some incomplete AREs and ARE half-sites, see Suppl. Table S2 for raw data in the de novo analyses), and they are independently produced for each dataset without a priori sequence information from the existing motif databases. The facts that a ciselement for only one other transcription factor besides AR is found within ARBs and that this factor is different for prostate, kidney and epididymis, strongly suggest biological relevance for these factors in AR binding to chromatin. The identity of the motifs that were found is more important than the exact number of hits present in each dataset. The computational sequence analysis does not tell us whether or not the cis-element-binding protein in question actually binds to a given site or the protein is even expressed in the tissue under study. However, information about these de novo motifs unique to each tissue prompted us to hypothesize that these factors play a role in AR binding and signalling. As a consequence, their genome-wide binding profiles and mRNA and protein expression levels were experimentally analysed and validated in the subsequent parts of the manuscript. Our response: We would like to reiterate that the de novo motif analyses (Figs. 4A-C) formed the basis for our hypothesis that chromatin binding of different transcription factors co-localize with that of AR in a genome-wide scale. In other words, the presence of a cis-element for a transcription factor adjacent to an AR binding sites means very little without direct evidence that the protein in question indeed binds to this site in a given cell type under physiological conditions. The results depicted in Fig. 4E show that this is indeed the case for a proportion of the sites but not for all of them. It is well known that no transcription factor binds to all potential cis-elements (that can be uncovered by bioinformatics tools) at a given time-point or condition, if ever. The "inconsistency" that the Reviewer refers to corresponds to the difference between a computational sequence analysis and an experimentally validated biological/physiological situation. Moreover, the computational sequence analysis results show enrichment of different closely related AP2 family members, whose consensus DNA binding sequences are very similar. Thus, it is possible that other AP2 family members could bind and co-operate with AR, for example, AR-2b that is also expressed in murine epididymis (see Suppl. Fig. S9 ).
(6) Given these issues with the motif analysis, Fig. 4D should also be regenerated, as new candidate cofactors are likely to be identified by changes to the experimental parameters.
Our response: Only cis-elements with the highest statistical significance (z score cut-off of 10 -10 , as mentioned in the legend to Fig. 4 , p. 30, lines 10-11) were used in producing Fig. 4D , so there is no way to be more stringent in the analysis parameters. Our response: To evaluate consequences of silencing in vivo is problematic, since knockout of Hnf4a or AP-2a is embryonically lethal in mice. Therefore, to examine the effects of their knockout in adult mice would require conditional gene silencing using tissue-specific inducible promoter to drive Cre recombinase expression. We were not able to procure mice with Hnf4a or AP-2a floxed alleles; for example, Jackson Laboratories was unable to produce live animals from cryopreserved embryos of Hnf4a-loxP mice. We also tried in mice a novel Hnf4a antagonist that has reportedly blocked DNA binding of Hnf4a in cell lines. However, in vivo pharmacokinetic properties of the compound BI6015 are not suitable for studying kidney, because of its high hepatic metabolism before entering systemic circulation (Kiselyuk et al, Chem Biol 2012, 19: 806-818) . Perhaps for this reason, we failed to see any changes in Hnf4a binding in mouse kidney after BI6015 treatment.
We tested a number of cell lines of murine epididymal or renal origin for expression of AR and the respective collaborating factors to perform silencing studies requested by the Reviewers and the Editor. A typical and well-known problem of these cells of epithelial origin is that they loose very quickly AR expression, and potentially also that of the collaborating transcription factor in question (Britan et al, Mol Cell Endocrinol 2004, 224: 41-53; Araki et al, J Androl 2002, 23: 854-869; Tabuchi et al, Biochem Biophys Res Commun 2005, 329: 812-823; Sipilä et al, Endocrinology 2004, 145: 437-446) . We found one epididymal cell line (mE-Cap28) that expresses an appreciable level of AR protein together with AP-2a. Silencing of AP-2a in this cell line diminishes AR binding to shared AR-AP-2a binding sites as indicated by direct ChIP-qPCR analyses (new Figure 7 , manuscript text p. 12, lines 1-13). We did not find an immortalized androgen-responsive kidney cell line that has an AR level high enough to permit ChIP assays. As a consequence, we turned to isolation and culturing of primary cells from renal cortex of adult mice, representing the ARexpressing proximal tubule epithelial cells. However, these primary cells from proximal tubules do not express Hnf4a under culture conditions (Suppl. Fig. S12A-B) . The same was also true for primary proximal tubule epithelial cells from kidneys of new-born mice obtained from a commercial vendor (ScienCell). Primary proximal tubule cells that we isolated or obtained from ScienCell express AR, but both cell lines have severely blunted androgen responsiveness, possible due to the lack of Hnf4a. Nevertheless, we studied under culture conditions AR loading onto a number of loci where, on the basis of our data, AR binds together with Hnf4a in renal tissue -that is, in vivo -and compared AR occupancy at these sites to those where AR binds in vivo without Hnf4a. Importantly, direct ChIP-PCR assays showed that in testosterone-exposed primary proximal tubule epithelial cells lacking Hnf4a, there is significant AR enrichment at AR-only sites, whereas AR binding is negligible at the loci corresponding to in vivo shared AR-Hnf4a sites. These results are shown in Supplementary Fig. S12C (manuscript text p. 12, lines 14-23).
(2) According to Figures 5A -5C (top panels), would AP-2α also regulated AR binding in Prostate and Kidney under hormone replacement conditions?
Our response: The data shown in Figs. 5A-C suggest that AP-2a binding sites co-localizes with ARBs not only in epididymis but also in prostate and kidney, and the ARB overlaps with AP-2a binding sites were shown in Suppl. Fig. 3 (which is now Suppl. Fig. 6B ) and commented on the manuscript text (p. 9, last 8 lines). However, the number of overlapping ARBs is considerably smaller than that of FoxA1 (prostate) and Hnf4a (kidney). For these particular overlapping sites, AP-2a binding is stronger than FoxA1 or Hnf4a binding (new Suppl . Fig. S6C ); thus, it is possible that it also plays a role for AR binding to these sites. This is now commented on manuscript text (p. 10, lines 1-5). However, studying these mechanisms in more detail would require a model system expressing all three proteins -that is, AR, AP-2a and Hnf4a -which, in view of our experience with various renal cell lines, would be challenging and beyond the scope of the present work.
(3) Do these factors have cooperative effects at their common binding sites (e.g. FKBP5), or are they mutually exclusive? The authors need to perform experiments to answer these questions.
Our response: This is an interesting question. However, we are at a loss to think about how to perform the suggested experiments in vivo. And as mentioned above, there are no suitable primary or established cell lines of murine prostate, renal or epididymal origin that could be used to address this issue.
Finally, the authors collected RNA after 3 days of testosterone treatment; however, they tested AR binding after only 2 hours. Did they perform microarray analysis at different time points to match the ChIP-seq data? Early transcription events following testosterone treatment should be evaluated before drawing conclusions about differentially regulated genes in these three tissues. For example, some Cluster 5 genes appearing to be down regulated in the prostate may be first up regulated directly in Day 1 and then down regulated indirectly in Day 3.
Our response: The three-day in vivo testosterone (T) treatment was chosen in order to get a comprehensive view of the androgen-responsive transcription program in each tissue. On the basis of existing literature, different androgen-responsive genes respond differently to T stimulation, and the full-scale in vivo effects need several days to develop (e.g., Gusb in kidney). Although it is true that some transcripts observed after a 3-day T exposure may be secondary and not primary androgenic effects, more than 80% of all up-regulated genes and more than 70% of the all downregulated genes reported in this manuscript possess an AR-binding event within ±100 kb of the transcription start sites, suggesting a direct AR involvement. Since the expression profiles were obtained at the same time interval for all three tissues examined, it is reasonable to conclude that the differences between the tissues represent real biological differences regardless of the modeprimary or secondary -of their regulation. Nevertheless, to address Reviewer's concerns, we performed gene expression profiling after shorter time intervals, that is, at 12 and 24 h after a single T injection. Overall, the results from these experiments with shorter T exposure times are very similar to those seen after the 3-day treatment, in that T-regulated transcription programs in prostate, kidney and epididymis were distinct, with only a very small number of overlapping genes (Suppl. Fig. S4 ). Even at early time points, there are genes up-regulated by androgens in one tissue and down-regulated in the other two tissues. Among all differentially regulated genes, there are less than five transcripts in each tissue that are upregulated as the primary response but then down-regulated after a longer T exposure (Suppl. Fig.  S4C ). With regard to the Reviewer's concern about transcripts in cluster 5, there are altogether 42 genes in this cluster, and among those genes, there is only one that is marginally up-regulated after 12 h but down-regulated at 24-h and 3-day time points. The results from gene expression profiling after shorter T exposure are now presented on p. 7, line 26 onwards.
Minor points

Details of ChIP-seq data should be included (uni-mapped reads).
Our response: This is now included as Supplementary Table S6 .
Most IGV visualization can be placed in the supplemental information.
Our response: We feel that IGV visualizations make important and clarifying points throughout the manuscript. However, some of the snapshots were removed or moved to the Supplementary information, for example in Our response: We do apologize for this mistake. The Reviewer is right in pointing out the importance of consistent scale usage when presenting ChIP-seq tracks, and we agree that scale should be same within each tissue. In fact, this was the case with the data presented, but an error was introduced in labelling the scale. This error is now corrected and the values double-checked from the original snapshots. Fig. 2B , the density figure needs to be plotted using a colour scale standard to the field. It is confusing to use white to show a moderate density of "4" -"6". The aggregate density curve should also be presented for each group, as weak binding seems to exist.
Our response: Even though we do not think that there is indeed "a colour scale standard in the field" for presenting these kinds of data, we have nevertheless amended the colour scales in Fig. 2B . The average density maps are now added as new Suppl. Fig. S1 and commented on in the text (p. 6, lines 1-4). Our response: Colour scale are changed and average density maps added; these are now present is a new Suppl. Fig. S6A . Fig. 5A -5C, 1,423 Our response: The scale bar is now included in Fig. 8 (previous Fig. 7 Our response: We agree with the Reviewer that silencing of Hnf4a and AP-2a would be highly interesting. Transgenic mouse models with floxed Hnf4a or AP-2a alleles were not available, and a novel Hnf4a antagonist BI6015 was not suitable for in vivo studies in mouse kidney (see our response to Reviewer #1, p. 3 of this letter). There are several epididymal and renal cell lines described in the literature as suggested by the Reviewer, but all the immortalized primary epithelial cells express low levels of AR -or no AR at all -and are poorly androgen-responsive under culture conditions. Moreover, they should also express the respective collaborating factors to perform the silencing studies. In other words, even though immortalized cell lines from various mouse tissues exist, many of them lack the characteristics that the corresponding cells have in the respective tissues under physiological conditions, which highlights the importance of in vivo data provided by our manuscript. In our case, we needed to have renal tubule epithelial cell line expressing both AR and Hnf4a proteins, and epididymal epithelial cell line expressing both AR and AP-2a proteins. Most primary epithelial cell lines lose their hormone-responsiveness and receptor expression fairly quickly when cultured in vitro, and this appears to be even more pronounced in immortalized cell lines -as is the case with most of the epididymal cell lines (Britan et al, Mol Cell Endocrinol 2004, 224: 41-53; Araki et al, J Androl 2002, 23: 854-869; Tabuchi et al, Biochem Biophys Res Commun 2005, 329: 812-823; Sipilä et al, Endocrinology 2004, 145: 437-446 ) and renal cell lines, for example, the PCT cells.
We found one epididymal epithelial cell line (mE-Cap28) that expresses an appreciable level of AR protein together with AP-2a. Silencing of AP-2a in this cell line diminishes AR binding to shared AR-AP-2a binding sites as indicated by direct ChIP-qPCR analyses (new Fig. 7 , manuscript text p. 12, lines 1-13). We did not find an immortalized renal epithelial cell line that has an AR level high enough to permit ChIP assays. In an attempt to overcome this problem, we produced primary cells from renal cortex of adult mice, representing the AR-expressing proximal tubule cells. However, these primary cells from proximal tubules do not express Hnf4a under culture conditions. The same was true for primary proximal tubule cells from kidneys of new-born mice obtained from a commercial vendor (ScienCell). Primary proximal tubule cells that we isolated or obtained from ScienCell express the Ar gene, but both cell lines have severely blunted AR responsiveness, possible due to the lack of Hnf4a protein. In any event, we studied under culture conditions AR loading onto a number of loci where AR binds together with Hnf4a in renal tissuethat is, in vivo -and compared AR occupancy at these sites to those where AR binds in vivo without Hnf4a. Importantly, direct ChIP-qPCR assays showed that in testosterone-exposed primary proximal tubule epithelial cells, there is significant AR enrichment at AR-only sites, whereas AR binding is negligible at loci corresponding to in vivo shared AR-Hnf4a sites. These results are shown in Supplementary Figure S12 (manuscript text p. 12, lines 14-23). (ChIP-seq) Our response: The requested experiments were carried out. In short, we performed gene expression profiling by using shorter time intervals (at 12 and 24 h after a single T injection). Overall, the results from these experiments with shorter T exposure times are very similar to those after the 3-day treatment, in that T-regulated transcriptomes in prostate, kidney and epididymis were distinct, with only a very small number of overlapping genes. These data are now shown in Supplementary  Fig. S4 (p. 7, line 26 onwards in manuscript text). See also our responses to Reviewer #1 (p. 5 of this letter). Figure 2A , the authors showed in a Venn diagram there is a large number of unique AR binding sites in all three tissues they examined. In Figure 4A, Figure 4E shows only a general overlap of AR with each transcription factor in the different tissues. It is possible the overlap observed is due to the nonunique AR binding sites.
The authors associated binding results
In
Our response: First, we would like to point out that we did not predict anything; we reported results from de novo motif search analyses by using SeqPos algorithm to identify cis-elements adjacent to the ARBs in each tissue (Figs. 4A-C) and then examined by using in vivo ChIP-seq assays how many of the potential binding sites were actually used by the transcription factor in question in each of the three murine tissues (Fig. 4E ).
As pointed out in our response to Reviewer #1 (pp. 1-2 of this letter), not all cis-elements in the genome that can be uncovered by bioinformatics tools for a given transcription factor are occupied by this factor. The enrichment of distinct cis-elements adjacent of the ARBs unique to each tissue suggests that these factors play a role in AR binding and signalling. Our data show that a significant proportion of ARBs in each tissue overlaps with the putative tissue-specific factors and that binding of the factors in question to chromatin precedes that of AR. The difference in the percentages in Figs. 4A-C and the overlapping numbers in Fig. 4E corresponds to the difference between a computational sequence analysis and an experimentally validated biological/physiological situation. Previous studies on prostate cancer and other cell lines have shown that pioneer (licensing) factors do not overlap by 100% with the steroid receptor-binding sites, and it is likely that other factors are needed as well. It is, however, clear from our data that FoxA1 -a generally accepted pioneer factor for AR -, cannot and does not play that role in all androgen-responsive tissues, and that Hnf4a in kidney and AP-2a in epididymis are strong candidates for functions similar to those that FoxA1 has in prostate.
Our data show unequivocally that each tissue has its own AR cistrome. Some of the binding sites are shared between the tissues; some are unique to each tissue. Obviously, we have not studied AR cistromes in all androgen-responsive tissues, implying that the shared and unique loci described in our work do not represent definitive lists of AR-binding events; AR may bind to the same sites in some other androgen-responsive tissues. Therefore, it is not conceivable that these tissue-specific transcription factors have a 100% overlap with the unique sites and no overlap with shared sites. Instead of definitive lists of unique binding events, our study provides insights into the determinants that are responsible for distinct, tissue-specific AR binding profiles. Suggested pioneering (licensing) factors in our study can also guide AR to sites utilized by AR in several tissues, but importantly, even if the AR binding site is the same, the collaborating factor is often tissue-specific, as exemplified by the Pgap2 gene locus (Fig. 6C) . Thus, it is reasonable to compare full cistromes of AR and respective collaborating factor in each tissue, as is done in Fig. 4E . However, to address the Reviewer's specific question about the overlap between unique AR-binding events and tissue-specific collaborating factors, we have now added this information to Suppl. Fig.  S5 . The unique sites show a somewhat greater overlap with shared AR-FoxA1 sites in prostate, shared AR-Hnf4a sites in kidney and shares AR-AP-2a sites in epididymis than the non-unique sites. This is now mentioned on p. 9 (lines 13-15) of the manuscript.
Our response: Our new results provide additional evidence to support functional significance of Hnf4a in kidney and AP-2a in epididymis in regulating AR binding to chromatin. Thus, AR is unable to bind to Hnf4a-marked (pioneered) sites in proximal epithelial cells and AP2a-marked sites in epididymal cells devoid or depleted of the respective pioneering (licensing) factors. Moreover, 60-74% of AR-Hnf4a sites in kidney and AR-AP-2a sites in epididymis reside in open chromatin environment, as evidenced by strong enrichment of H3K4me1 and H3K27ac histone marks (Suppl .  Fig. S10) ; moreover, H3K4me1 and H3K27ac average tag densities at AR-Hnf4a sites in kidney and AR-AP-2a sites in epididymis show typical tag profile of active enhancers (Fig. 5D , manuscript text p. 11). In view of this new information, we feel that our statements are well justified.
The authors report AR binding profiles in mouse tissues (prostate, kidney and epididymis). Based on integrating this data with gene expression profiles and undertaking motif enrichment analysis they report tissue-specific AR binding profiles which are dependent on different factors depending on the tissue. AR binding in prostate is attributed to FoxA1, AR binding in kidney is attributed to HNF4α and AR binding in epididymis is attributed to AP-2α. Our response: We appreciate the Reviewer's comment on the high technical quality of our work. Experimental procedures and the amount of starting material are now described in more detail in Materials and Methods (p. 18, lines 1-5) and in Suppl. Table S4 . We also believe that one of the reasons for the high-quality in vivo ChIP-seq data is the AR antibody that we have used. This antibody is a polyclonal rabbit antibody raised against a full-length rat AR purified to homogeneity (Karvonen et al, J Biol Chem 1997 271: 15973-15979) as opposed to the commercial antibody raised against the 20 amino-terminal AR residues used by most other groups in the field. We believe that the immunohistochemical results shown in Fig. 8 (former Fig. 7 ) address the question of cells expressing AR and the proposed licensing factor.
The public link for the datasets deposited into GEO database will not work before the manuscript is this tissue-based AR 'descriptome' represents a technical leap forward based on the amounts of material used and consequently a first in these tissues but does not open up new experimental or conceptual avenues beyond that.
Our response: We believe that our in vivo results provide significant new perspectives into tissuespecific functions of the AR under physiological conditions, despite the fact that previous work on cancer cell lines has revealed several aspects about context-specific AR recruitment. Most of the genome-wide studies regarding AR function have been performed in prostate cancer cells lines and have highlighted the importance of FoxA1 in AR function. Our results present a very important mechanistic concept by showing that FoxA1 is a key regulator for AR in prostate, but not in every other androgen target tissue. Moreover, identification by in vivo experiments of two novel licensing factors for AR -AP-2a in epididymis and Hnf4a in kidney -represents an important advance in the field. Thank you very much for submitting a revised version of your study to The EMBO Journal that has now been seen by the original referees. Please accept my apologies for the slight delay in communicating a final outcome. You will see that further consultations were necessary upon the divided opinions from the referees regarding further-reaching functional support. Having engaged the initial third referee for arbitration, I am now in a position to offer further pursuit at our title.
For this, I kindly ask you to strictly follow ref#1's remarks and perform the motif scanning on all ARBs in each tissue for each pertinent motif to possibly gather a more thorough view on motif distribution. Conditioned on this, and as encouraged by the arbitrating referee, I am happy to wave ref#2's request for further functional attempts but suggest to reconsider the title for a more objective presentation of the content of the study.
Thus, please perform/integrate the bioinformatics part and return an ultimate version to The EMBO Journal to your earliest convenience.
Please do not hesitate to get in touch in case of further questions.
I look forward to hear from you/receive a final version.
P.S. At this stage, we would also require a short synopsis, i.e. 2-5 bullet points summarizing the major advance provided by your study.
REFEREE REPORTS:
Referee #1:
I am truly pleased with the efforts put forth by the authors to thoroughly address the other reviewers' comments and ours. The technical hurdles overcome to provide some insight into the tissue-specific pioneering activity of HNF4a and AP-2a is commendable and the results are compelling. Overall, the manuscript has improved significantly since its previous iteration, yet one major critique remains. The authors have now clearly explained that the de novo motif identification was performed for a subset of ARBs in each tissue (i.e. all prostate-unique ARBs, or the top 5000 tissuespecific ARBs in kidney and epididymis). I appreciate the technical constraints of performing de novo motif calling on large datasets and see no issues in using the current approach for initial identification and hypothesis generation. I feel an essential step is to then implement a motif scanning approach on all ARBs in each tissue for each of the pertinent motifs. In this way, you may overcome an apparent bias in your current results (as we mentioned previously, there are no reports of a full-length ARE being found in 70-99% of ARBs, low ranked ARBs may exhibit half-site
